Thyroid substitution may be a risk factor for Covid-19

International audienc

Pharmacist-led medication reconciliation at patient discharge: a tool to reduce healthcare utilization? an observational study in patients 65 years or older

International audienceAbstract Background Older patients often experience adverse drug events (ADEs) after discharge that may lead to unplanned readmission. Medication Reconciliation (MR) reduces medication errors that lead to ADEs, but results on healthcare utilization are still controversial. This study aimed to assess the effect of MR at discharge (MRd) provided to patients aged over 65 on their unplanned rehospitalization within 30 days and on both patients’ experience of discharge and their knowledge of their medication. Methods An observational multicenter prospective study was conducted in 5 hospitals in Brittany, France. Results Patients who received both MR on admission (MRa) and MRd did not have significantly fewer deaths, unplanned rehospitalizations and/or emergency visits related to ADEs (OR = 1.6 [0.7 to 3.6]) or whatever the cause ( p = 0.960) 30 days after discharge than patients receiving MRa alone. However, patients receiving both MRa and MRd were more likely to feel that their discharge from the hospital was well organized ( p = 0.003) and reported more frequently that their community pharmacist received information about their hospital stay ( p = 0.036). Conclusions This study found no effect of MRd on healthcare utilization 30 days after discharge in patients over 65, but the process improved patients’ experiences of care continuity. Further studies are needed to better understand this positive impact on their drug care pathway in order to improve patients’ ownership of their drugs, which is still insufficient. Improving both the interview step between pharmacist and patient before discharge and the transmission of information from the hospital to primary care professionals is needed to enhance MR effectiveness. Trial registration NCT04018781 July 15, 2019

A catalog of numerical centrosome defects in epithelial ovarian cancers

International audienceCentrosome amplification, the presence of more than two centrosomes in a cell is a common feature of most human cancer celllines. However, little is known about centrosome numbers inhuman cancers and whether amplification or other numericalaberrations are frequently present. To address this question, wehave analyzed a large cohort of primary human epithelial ovariancancers (EOCs) from 100 patients. We found that rigorous quantitation of centrosome number in tumor samples was extremelychallenging due to tumor heterogeneity and extensive tissue disorganization. Interestingly, even if centrosome clusters could beidentified, the incidence of centrosome amplification was not comparable to what has been described in cultured cancer cells. Surprisingly, centrosome loss events where a few or many nuclei werenot associated with centrosomes were clearly noticed and overallmore frequent than centrosome amplification. Our findings highlight the difficulty of characterizing centrosome numbers inhuman tumors, while revealing a novel paradigm of centrosomenumber defects in EOCs